Total Payments
$193,634
2024 Payments
$9,953
Companies
9
Transactions
154
Medicare Patients
70
Medicare Billing
$15,430
Payment Breakdown by Category
Consulting$93,482 (48.3%)
Other$58,900 (30.4%)
Research$32,593 (16.8%)
Travel$6,325 (3.3%)
Food & Beverage$2,334 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $93,482 | 23 | 48.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,700 | 54 | 28.2% |
| Unspecified | $32,593 | 31 | 16.8% |
| Travel and Lodging | $6,325 | 17 | 3.3% |
| Honoraria | $4,200 | 1 | 2.2% |
| Food and Beverage | $2,334 | 28 | 1.2% |
Payments by Type
General
$161,041
123 transactions
Research
$32,593
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $79,589 | 81 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $53,987 | 27 | $0 (2024) |
| Blueprint Medicines Corporation | $28,111 | 17 | $0 (2024) |
| Novartis Pharma AG | $11,990 | 10 | $0 (2024) |
| Incyte Corporation | $8,480 | 11 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,656 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $5,200 | 1 | $0 (2023) |
| Promega Corporation | $590.94 | 2 | $0 (2024) |
| Astellas Pharma Global Development | $30.05 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,953 | 15 | Novartis Pharma AG ($2,916) |
| 2023 | $25,519 | 18 | NOVARTIS PHARMACEUTICALS CORPORATION ($13,085) |
| 2022 | $40,216 | 20 | Blueprint Medicines Corporation ($23,832) |
| 2021 | $26,068 | 14 | Novartis Pharmaceuticals Corporation ($14,278) |
| 2020 | $22,223 | 10 | Novartis Pharmaceuticals Corporation ($12,773) |
| 2019 | $25,076 | 23 | Novartis Pharmaceuticals Corporation ($8,995) |
| 2018 | $22,928 | 23 | PFIZER INC. ($22,910) |
| 2017 | $21,651 | 31 | PFIZER INC. ($18,937) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Blueprint Medicines Corporation | — | Food and Beverage | Cash or cash equivalent | $41.66 | General |
| 12/07/2024 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $31.60 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Travel and Lodging | In-kind items and services | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 09/28/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $391.86 | Research |
| Study: CABL001X2101 • Category: ONCOLOGY | ||||||
| 09/26/2024 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $130.56 | General |
| 09/04/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $720.50 | Research |
| Study: CABL001AUS04 • Category: Oncology | ||||||
| 06/16/2024 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $79.69 | General |
| 05/18/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $73.92 | General |
| Category: Oncology / Rare Diseases | ||||||
| 05/09/2024 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,460.00 | General |
| 05/08/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $162.05 | Research |
| Study: CABL001X2101 • Category: ONCOLOGY | ||||||
| 04/24/2024 | Promega Corporation | — | Food and Beverage | In-kind items and services | $349.54 | General |
| 04/24/2024 | Promega Corporation | — | Travel and Lodging | Cash or cash equivalent | $241.40 | General |
| 03/08/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,282.76 | Research |
| Study: CABL001X2101 • Category: Oncology | ||||||
| 01/24/2024 | Novartis Pharma AG | GLEEVEC (Drug), SCEMBLIX | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $2,002.00 | General |
| 12/08/2023 | Novartis Pharma AG | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $50.61 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $4,387.50 | General |
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | In-kind items and services | $296.59 | General |
| 11/19/2023 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $42.42 | General |
| 11/19/2023 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $28.99 | General |
| 11/18/2023 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $134.29 | General |
| 11/18/2023 | Blueprint Medicines Corporation | — | Travel and Lodging | In-kind items and services | $121.96 | General |
| 11/18/2023 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $54.37 | General |
| 11/18/2023 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $29.87 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BOSUTINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $22,380 | 22 |
| CABL001AUS04 | Novartis Pharmaceuticals Corporation | $5,072 | 2 |
| AN OPEN LABEL, MULTI-CENTER PHASE IIIB STUDY OF ASCIMINIB (ABL001) MONOTHERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA ON CHRONIC PHASE (CML-CP) PREVIOUSLY TREATED WITH AT LEAST 2 PRIOR TKIS (TYROSINE KINASE INHIBITORS) | Novartis Pharmaceuticals Corporation | $2,160 | 1 |
| CABL001X2101 | Novartis Pharmaceuticals Corporation | $1,283 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $749.58 | 2 |
| CABL001X2101 | Novartis Pharma AG | $553.91 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $395.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 21 | 41 | $11,997 | $4,377 |
| 2020 | 3 | 49 | 118 | $30,092 | $11,052 |
Total Patients
70
Total Services
159
Medicare Billing
$15,430
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 21 | 41 | $11,997 | $4,377 | 36.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 77 | $16,477 | $6,489 | 39.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 20 | 28 | $8,193 | $2,436 | 29.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 13 | $5,422 | $2,127 | 39.2% |
About Dr. Michael Deininger, MD
Dr. Michael Deininger, MD is a Hematology healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932115524.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Deininger, MD has received a total of $193,634 in payments from pharmaceutical and medical device companies, with $9,953 received in 2024. These payments were reported across 154 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($93,482).
As a Medicare-enrolled provider, Deininger has provided services to 70 Medicare beneficiaries, totaling 159 services with total Medicare billing of $15,430. Data is available for 2 years (2020–2021), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location Milwaukee, WI
- Active Since 08/01/2006
- Last Updated 04/07/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1932115524
Products in Payments
- BOSULIF (Drug) $70,189
- SCEMBLIX (Drug) $16,103
- TASIGNA (Drug) $11,710
- ABL002 (Drug) $8,843
- DAURISMO (Drug) $6,780
- ICLUSIG (Drug) $5,656
- GLEEVEC (Drug) $2,363
- AYVAKIT (Drug) $107.73
- Xospata (Drug) $30.05
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.